Targeting triple-negative breast cancer cells with a β1-integrin binding aptamer

• Main Authors: Karlis Pleiko (Author), Maarja Haugas (Author), Vadims Parfejevs (Author), Teodors Pantelejevs (Author), Emilio Parisini (Author), Tambet Teesalu (Author), Una Riekstina (Author)
• Format: Book
• Published: Elsevier, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2162-2531; 10.1016/j.omtn.2023.08.015
• Keywords: MT: Oligonucleotides: Therapies and Applications; aptamer; β1-integrin; aptamer internalization; proximity labeling; affinity ligands; Therapeutics. Pharmacology; RM1-950
• Source: Molecular Therapy: Nucleic Acids, Vol 33, Iss , Pp 871-884 (2023)

Targeted therapies have increased the treatment options for triple-negative breast cancer patients. However, the paucity of targetable biomarkers and tumor heterogeneity have limited the ability of precision-guided interventions to live up to their full potential. As affinity-targeting ligands, aptamers show high selectivity toward target molecules. Compared with antibodies, aptamers have lower molecular weight, increased stability during transportation, reduced immunogenicity, and increased tissue uptake. Recently, we reported discovery of the GreenB1 aptamer, which is internalized in cultured triple-negative MDA-MB-231 human breast cancer cells. We show that the GreenB1 aptamer specifically targets β1-integrin, a protein linked previously to breast cancer cell invasiveness and migration. Aptamer binds to β1-integrin with low nanomolar affinity. Our findings suggest potential applications for GreenB1-guided precision agents for diagnosis and therapy of cancers overexpressing β1-integrin.